Power Law company profile

Carlsmed

Biotech & Life Sciences · United States · Founded 2018 · IPO 2025 Colt

Carlsmed is personalized surgical implants for patients with debilitating spine deformities

Valuation

$149M

Market cap · May/2026

Revenue

$51M

Latest reported FY

Featured in $1B+ revenueColt · Power Law growth-stage

Investors

5 investors on Carlsmed's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage

The Cove Fund

Wavemaker Three-Sixty Health

Series A 2 investors entered at this stage

U.S. Venture Partners

The Vertical Group

Series B+ 1 investor entered at this stage

B Capital

Global footprint

Where Carlsmed has talent and traffic

AI talent share

0.7% of workforce is AI talent
(1 of 137 staff)

Core AI10.73%

Other AI00%

Non-AI workforce13699.27%

Workforce by country

🇺🇸 United States HQ

Book a demo for the full country breakdown

Web traffic by country

4.5K monthly visits
across markets

🇺🇸 United States93.3%

🇮🇳 India6.7%

Top 2 markets shown

Market sentiment

What the market is saying about Carlsmed

An AI-synthesized read of the highest-engagement posts about Carlsmed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Carlsmed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles